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Cognitive impairment and behavioural disorders are often encountered in subjects with Parkinson’s disease (PD). A simple PD-
related frontostriatal cognitive dysfunction (PDFCD) staging is proposed. Executive dysfunction and mental fatigue (stage I),
depression/anxiety (stage IIa), apathy/pain (stage IIb), and dementia (stage III) reﬂect a sequential process of dopamine depletion
occurring in diﬀerent regions of the striatum (stages I and II) and the frontal cortex (stage III). In addition to these nonmotor
manifestations present in the unmedicated (OFF) state, the PDFCD model also predicts a number of complications related to
dopaminergic treatment (ON state), from impulse control disorders (stages I and IIa) to hallucinations (stage IIb) and psychosis
(stage III). Although the model admittedly needs further reﬁnements, it provides a framework for hypothesis testing and may help
clinicians optimize therapeutic strategies.
1.Introduction
Parkinson’s disease (PD) is biochemically characterized by
dopamine depletion [1, 2]. Although the loss of dopamine is
particularly severe in the putamen, which explains the motor
manifestations of the disease, other dopaminergic projec-
tions are also aﬀected and contribute to the development of
cognitive impairment and neuropsychiatric disorders [3, 4].
Thus, some degree of executive dysfunction is a virtually
constant ﬁnding in PD, even in the early stages of the disease
[5]. Apathy, depression, anxiety, and fatigue are present in
one third of patients [6], and pain is also common [7].
Similarly, it has been estimated that approximately one third
of PD subjects end up developing dementia [3, 4]. In this
review, I will use a simple model to correlate these non-
motor manifestations of the disease with diﬀerent stages
of frontostriatal dysfunction caused by dopamine depletion
sequentially occurring in diﬀerent regions of the striatum
and the frontal cortex [8–11].
The PD-related frontostriatal cognitive dysfunction
(PDFCD) staging here proposed (Figure 1) assumes that
dopamine-dependent frontostriatal functioning follows an
inverted U-shaped dose-response curve (Figure 2). The
PDFCD model is mostly based on neuroimaging data and
clinicalobservations, andoﬀersstage-speciﬁcclinicalpredic-
tions oﬀ and on dopaminergic medication.
2. Dopamine Depletion and Dysfunction of
FrontostriatalLoops
PD is characterized by a gradient of dopamine depletion
in the striatum, with the putamen being the most aﬀected
region, followed by the dorsal caudate, and then the
ventral striatum (ventral caudate and nucleus accumbens)
[1, 2]. A combination of PD-speciﬁc and aging-related
dopamine depletion [12, 13] determines the degree of
cognitive/behavioural dysfunction.
Three major anatomical and functional frontostriatal
loops are proposed to be sequentially aﬀected in PD: ﬁrst,
the motor loop, which connects the supplementary motor
area with the putamen; second, the cognitive loop, which
connects the dorsolateral prefrontal cortex (DLPFC) with
the dorsal caudate nucleus; and third, a “complex” limbic
loop, with connections between the orbitofrontal cortex
(OFC) and the ventral caudate nucleus, and between the
anterior cingulate cortex (ACC) and the nucleus accumbens.
These three functional frontostriatal loops have been well
characterized both theoretically and experimentally [8–11].2 Parkinson’s Disease
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Figure 1: Parkinson’s disease-related frontostriatal cognitive dysfunction (PDFCD) staging. Three major frontostriatal loops are shown:
(1) the loop connecting the dorsolateral prefrontal cortex (DLPFC) with the dorsal caudate nucleus (d-Caud), (2) the loop connecting the
orbitofrontal cortex (OFC) with the ventral caudate nucleus (v-Caud), and (3) the loop connecting the anterior cingulate cortex (ACC) with
the nucleus accumbens (NAcc). Dopamine (DA) projections for these loops, as well as the direct dopaminergic projection to the frontal
cortex, are schematically shown. Major symptoms, OFF and ON dopaminergic treatment, are detailed. ICDs: impulse control disorders.
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Figure 2: Parkinson’s disease related frontostriatal cognitive dysfunction (PDFCD) staging with region-speciﬁc dopamine (DA) levels.
Dopamine-related frontostriatal functioning is assumed to follow an inverted U-shaped dose-response curve. Predicted stage-speciﬁc
dopaminergic function, both oﬀ and on dopaminergic treatment, is shown for dorsal caudate (d-Caud), ventral caudate (v-Caud), nucleus
accumbens (NAcc) and frontal cortex. In the ON state, the inverted U-shaped curves represent DA levels if the patient is on levodopa, and
DA tone if the patient is on a dopamine agonist. The direct dopaminergic projection to the frontal cortex seems to be initially upregulated,
but with limited capability to increase further the dopaminergic tone in response to dopaminergic treatment (see text for details). ICDs =
impulse control disorders.
In more advanced PD, the direct dopaminergic projection
to the frontal cortex becomes also aﬀected, leading to
cortical dopamine depletion [14, 15]. There is evidence that
the release of dopamine, at both the striatal and cortical
level, facilitates loop functioning [8–11]. Alterations in the
motor loop are crucial because they serve to make the
clinical diagnosis, signalling that PD pathology has reached
midbrain dopamine cells [16]. However, the PDFCD model
only applies to the cognitive/limbic loops and the direct
dopaminergic projection to the frontal cortex.
In the early stages of PD, frontal lobe dysfunction
is assumed to reﬂect cortical “deaﬀerentation” in relationParkinson’s Disease 3
to striatal dopamine depletion. At later stages, cortical
dopaminedepletionlikelycontributestofrontallobeimpair-
ment. In keeping with this notion, dementia in PD is related
to the loss of dopamine cells in the medial part of the
substantia nigra pars compacta [17] and ventral tegmen-
tal area [18], regions that originate direct dopaminergic
projections to the cortex. Interindividual variability in the
time course and degree of dopamine depletion in diﬀerent
striatal and frontal regions may explain the wide range of
clinical manifestations encountered in PD. Although the
PDFCDmodelisonlybasedonstriatalandfrontaldopamine
depletion, cortical Lewy body pathology, which typically
occurs in advanced PD [16], will eventually contribute to the
development of frank dementia [16, 19].
3. PDFCDStage I: The Frontostriatal
Cognitive Loop
3.1. Functional Analysis. The frontostriatal cognitive loop
(DLPFC—dorsal caudate nucleus) is involved in executive
function [5]. Normal performance of typical cognitive
frontal lobe tasks, such as the Wisconsin Card Sorting
Task or the Tower of London planning task, depends upon
several frontal executive functions including working mem-
ory, attention, planning, and cognitive ﬂexibility, all of them
pertaining to this frontostriatal loop [20–23]. PD subjects
oﬀ medication have impaired task set-shifting [24, 25],
reduced basal ganglia activation during performance of
the Tower of London test [26, 27], and show correlations
between the degree of impairment on executive tasks and
the degree of dopaminergic hypofunction in the caudate
nucleus [28, 29]. These alterations are virtually constant
in PD and suggest frontal lobe “deaﬀerentation” caused
by dopamine depletion in the dorsal caudate nucleus [24,
30]. There is some indication that such a “deaﬀerentation”
predicts incident dementia [31]. Interestingly, the direct
dopaminergic projection to the prefrontal cortex seems
to be hyperactive early in the course of the disease [32,
33], presumably as a compensatory mechanism (Figure 2).
Nonetheless, dorsal caudate-dependent tasks are consistently
associated with DLPFC hypoactivation [34].
3.2. Clinical Correlates
3.2.1. OFF Dopaminergic Treatment. Clinical manifestations
of frontal lobe dysfunction, including poor planning, defects
in set-shifting, impaired working memory, and executive
dysfunction, are common in PD without dementia [35]
and correlate with a PD-related cognitive pattern of altered
glucose metabolism [36]. This pattern is characterized by
metabolic reductions in frontal areas, and relative metabolic
increases, presumably compensatory, in the cerebellum.
Fatigue (mental fatigue) can be present in PDFCD stage I
(Figures 1 and 2) and may even precede the onset of motor
symptoms [6].
3.2.2. ON Dopaminergic Treatment. Dopaminergic treat-
ment induces impulse control disorders (ICDs) in a number
of PD subjects as the result of the overactivation of the
“complex” frontostriatal limbic loop [37]. Hence, ICDs
occur in PDFCD stages I and IIa (Figure 2;s e en e x t
section for further details). In contrast to the dopaminergic
projections to the striatum, the activity of the dopaminergic
projection to the frontal cortex is not expected to be
substantially altered by dopaminergic treatment, especially
when it is overactive, because it lacks dopamine transporter
sites and dopamine D2 autoreceptors [38]. In fact, the action
of dopamine in the frontal cortex is mostly mediated by
dopamine D1 receptors [39]. This might explain some of the
clinical diﬀerences between levodopa therapy and treatment
with direct dopamine agonists. While levodopa-derived
dopamine stimulates D1 and D2 receptors, dopamine ago-
nists predominantly stimulate D2 receptors.
4. PDFCDStage II:The “Complex”
FrontostriatalLimbic Loop
4.1. Functional Analysis. In PD, the damage to the dopamin-
ergic projection to the ventral striatum (ventral caudate
and nucleus accumbens) is less prominent than the damage
to the dopaminergic projection to the dorsal striatum
(putamen and dorsal caudate) [1, 12]. Still, ventral regions
of the striatum also undergo substantial dopamine depletion
(∼60% dopamine loss) [1, 13].
Reversal learning tasks, which basically test for balance
between “go” and “no-go” signals [40], are used to assess the
“complex” frontostriatal limbic loop (OFC/ACC—ventral
caudate/nucleus accumbens) [41]. As one would predict
according to the regional diﬀerences in the degree of
striatal dopamine depletion, PD subjects oﬀ medication
perform much better in reversal learning tasks than in
tasks involving the dorsal caudate circuitry [10, 41–43].
Conversely, dopaminergic therapy improves dorsal caudate
related tasks and worsens reversal learning tasks [10, 41,
42]. This paradoxical eﬀect of medication is probably due
to the “over-dose” of a relatively normal ventral striatum
[10, 42–45]. PD subjects tend to avoid negative outcomes
when being oﬀ medication, and they are sensitive to positive
outcomes when being on medication [40]. In other words,
dopaminergic therapy favours “go” signals over “no-go”
signals.
4.2. Clinical Correlates. Although it is admittedly diﬃcult to
functionally separate the two components of the “complex”
frontostriatal limbic loop, there is some suggestion that the
OFC—ventral caudate circuit modulates social/emotional
behaviour and the ACC—nucleus accumbens circuit medi-
atesmotivationandintegratescognitiveandemotionalitera-
tivenetworks[9].Consequently,hypoactivationofthelimbic
loop, speciﬁcally the ACC—nucleus accumbens circuit, is
expected to lead to apathy. Limbic loop hyperactivation, on
the other hand, is expected to lead to impulsive behaviours.
4.2.1. OFF Dopaminergic Treatment. Depression, anxiety,
a n da p a t h ya r ec o m m o ni nP D[ 6, 46, 47]. Apathy still needs
a clear deﬁnition. Most authors would agree that it refers4 Parkinson’s Disease
to a lack of motivation [48]. In any case, it is increasingly
recognized that apathy is not depression, although both
disordersshareanumberofclinicalcharacteristics,including
psychomotor retardation, diminished interest, anergy, and
lack of insight [49]. The proof of concept for a distinction
between apathy and depression came from the observation
that non-PD-depressed patients treated with selective sero-
tonin reuptake inhibitors (SSRIs) sometimes develop apathy
[50, 51].
Some imaging studies suggest that depression in PD is
associated with dopamine depletion in the ventral striatum
[52] and hypoactivation of the cingulate cortex [53, 54].
However, these results may need to be reassessed in view of
the increasing awareness of a distinction between depression
and apathy. Recent estimates suggest that apathy is more
prevalent than depression in PD [6, 47], suggesting that
many patients who are assumed to have depression could
have apathy instead. In non-PD patients with depression,
the ACC (speciﬁcally, its subgenual portion) has been found
to be hyperactive, not hypoactive [55–57]. In addition,
pathological and neuroimaging observations in Alzheimer’s
disease, where apathy is a very common phenomenon
[47], indicate that there is a correlation between apathy
and neuroﬁbrillary tangles burden in the anterior cingulate
cortex [58–60]. Likewise, apathy in PD correlates with
reduced gray matter in the cingulate cortex [61]. Taken
together, these observations suggest that depression corre-
sponds to PDFCD stage IIa (hypofunction of the OFC—
ventral caudate circuit), and apathy corresponds to PDFCD
stage IIb (hypofunction of the ACC—nucleus accumbens
circuit) (Figures 1 and 2). Naturally, PDFCD stage IIb also
includes hypofunction of the OFC—ventral caudate circuit,
whichexplainswhydepressionandapathyoccursequentially
and share several clinical characteristics.
Depression is sometimes a premotor manifestation of
PD but more often appears after motor symptom onset
[6, 46]. The underlying neurochemical bases may diﬀer in
both scenarios. Depression occurring during the pre-motor
phase of the disease probably reﬂects Lewy pathology in
raphe nuclei and locus coeruleus, originating serotonergic
and noradrenergic abnormalities [16]. Accordingly, depres-
sion preceding PD motor symptoms should respond to
conventional antidepressants, including SSRIs. Nonetheless,
recent neuroimaging studies have challenged this concept
by showing preserved serotonin transporter binding in the
novo PD subjects [62]. The neurochemical basis of pre-
motor depression remains, therefore, unclear; dopamine
dysfunction could play a role. Depression occurring at later
stages, on the other hand, is likely related to dopamine
depletion in the ventral caudate (PDFCD stage IIa; Figure 2).
In this case, treatment is problematic. Many antidepressants,
particularly SSRIs, have failed to demonstrate eﬃcacy in PD
[63, 64]. In fact, SSRIs can paradoxically precipitate apathy.
Neuroimaging studies provide some clues to explain this
phenomenon. In non-PD subjects with major depression,
antidepressants correct ACC overactivity and there is a
correlation between the degree of relative ACC overactivity
at baseline and the response to antidepressants [55]. In PD,
treatment with SSRIs can lead to apathy by decreasing the
activity of the ACC—nucleus accumbens circuit (i.e., SSRI-
related functional transition from stage IIa to stage IIb).
Anxiety typically occurs during the motor phase of
PD [6, 46]. Although other neurotransmitters are in all
likelihood responsible for anxiety during the pre-motor
phase of the disease, dopamine depletion in the ventral
striatum seems to play a major role once the motor
symptoms are established. Thus, the severity of anxiety
is inversely correlated with dopamine/noradrenaline trans-
porter binding in caudate, ventral striatum, and amygdala
[52]. Animal experiments indicate that stress is associated
with decreased dopamine release in the nucleus accumbens
and increased dopamine release in the medial prefrontal
cortex [65]. This observation suggests that anxiety occurs
when the ACC—nucleus accumbens circuit is hypoactive
and the direct dopaminergic projection to the frontal cortex
is still functionally preserved (PDFCD stage IIb; Figure 2).
However,PDsubjectsondopaminergictherapyoftenpresent
with a combination of depression and anxiety during the
OFF periods, suggesting a connection between anxiety and
PDFCD stage IIa. PD-related functional or pathological
alterations in the amygdala [66], a limbic structure known
to play an important role in anxiety disorders [67], could
ultimately determine whether anxiety occurs in PDFCD
stage IIa or stage IIb.
Apathy in PD is proposed to be associated with hypo-
function of the ACC—nucleus accumbens circuit (PDFCD
stage IIb; Figure 2). A recent study reported apathy in 23%
of drug-na¨ ı v eP Ds u b j e c t s[ 68], indicating that the limbic
loop can be dysfunctional early in the course of the disease.
At later stages, when PD subjects develop a combination of
striatal and frontal dopamine depletion (PDFCD stage III),
apathy is expected to become more prevalent and severe,
with even further progression in more advanced PD, with
the development of frontal Lewy body pathology [16, 19].
In this context, subjects with frontotemporal dementia have
the highest prevalence rates of apathy across disorders with
frontal dysfunction [47].
Pain is a nonmotor manifestation of PD known to
be inﬂuenced by dopaminergic treatment [7, 69]. The
PDFCD model suggests that pain (central pain) is related to
dopamine depletion in the ventral striatum, speciﬁcally in
the nucleus accumbens (PDFCD stage IIb; Figure 2). In sup-
port of this view, there is experimental evidence suggesting
thatthenucleusaccumbensisinvolvedinadopamine-opioid
network that modulates pain transmission [70, 71]. Pain
is sometimes directly related to poor motor performance
(dystonic pain) [7], reﬂecting dopamine depletion in the
putamen.
It has already been mentioned that fatigue (mental
fatigue) can be an early symptom of PD (PDFCD stage I)
[6, 72]. More often, however, it is associated with depression
and reduced motivation [6, 73], signalling PDFCD stages
IIa and IIb, and possibly stage III as well. Serotonergic
dysfunction may contribute to fatigue [74].
4.2.2. ON Dopaminergic Treatment. Remarkably, the
PDFCD model suggests that depression can be present
during ON periods in stages IIa and IIb (Figure 2),Parkinson’s Disease 5
explaining a relatively common clinical observation (i.e., PD
subjects who are depressed oﬀ and on medication).
Clinical studies suggest that some 10% of PD sub-
jects treated with dopaminergic medications develop ICDs,
including pathological gambling, compulsive shopping,
compulsive eating, hypersexuality, and even addictive
behaviours [75, 76]. The PDFCD model suggests that ICDs
are due to treatment-related hyperactivations of the ACC—
nucleus accumbens circuit, and should therefore occur
in stages I and IIa (Figure 2). Experimental observations
support this notion [77–79]. PD subjects with the so-
called “dopamine dysregulation syndrome” (i.e., subjects
with abusive use of anti-PD medication) release large
amounts of dopamine in the ventral striatum after levodopa
administration[77].Itisknownthatthereleaseofdopamine
in the nucleus accumbens has rewarding eﬀects [80], which
would lead to the perpetuation of impulsive behaviours.
Naturally, dopamine-related increases in the dopaminergic
tone of the ventral striatum are expected to cause hyper-
activation of ACC and OFC. In keeping with the PDFCD
model, imaging studies in non-PD subjects with obsessive-
compulsive disorder have shown decreased dopamine D2
binding—highly suggestive of increased dopamine levels—
in the ventral striatum, and hyperactivation of OFC and
ACC [81–84]. As the caudate nucleus modulates abnormal
behaviours [5, 85], it could be tentatively argued that
primarily compulsive behaviours (e.g., punding) might be
more common in PDFCD stage I, and primarily reward-
related ICDs (e.g., pathological gambling) might be more
common in PDFCD stage IIa. In this context, ICDs in
PD are associated with depression, anxiety, and obsessive-
compulsive symptoms [86]. Clinical studies suggest that
young PD subjects are at high risk of developing ICDs
[76], perhaps in relation to age-dependent dopamine release
dynamics [87]. Younger PD subjects release more dopamine,
and at a faster rate, than older PD subjects.
Treatment-related visual hallucinations sometimes her-
ald the development of dementia [6]. The PDFCD model
suggests that, by the time the ﬁrst hallucinations appear,
all the dopamine-dependent frontostriatal loops are already
dysfunctional (hypoactive) in the OFF state, whereas the
dopaminergic projection to the frontal cortex is still pre-
served (PDFCD stage IIb; Figure 2). In this situation, frontal
dopamine levels are expected to increase in response to
dopaminergic treatment (ON state), possibly explaining why
visual hallucinations are associated with relative frontal
hypermetabolism [88]. Nonetheless, visual hallucinations
in PD are also linked to hypometabolism in occipitotem-
poroparietal regions [89].
5. PDFCDStage III: The Dopaminergic
Projection to the Frontal Cortex
The damage to the direct dopaminergic projection to the
frontal cortex signals the beginning of dementia [17, 18]. At
this stage (PDFCD stage III; Figure 2), the patient begins to
oscillate between dementia in the OFF state and psychosis
in the ON state, a cycle that becomes more pronounced and
fullyestablishedinmoreadvancedPD,withthedevelopment
of cortical Lewy body pathology. Other times, the patient
remains apathetic during both OFF and ON periods.
In addition to striatal and frontal dopamine depletion,
other neurotransmitters are also involved in PD dementia.
Indeed, cortical cholinergic dysfunction can be even more
severe in PD subjects with dementia than in patients with
Alzheimer’s disease [90, 91]. In advanced PD, cortical
pathology—not only Lewy bodies but also neuroﬁbrillary
tangles and amyloid deposits—becomes a major contribut-
ing factor. Thus, in vivo PET studies have found comparable
levels of cortical amyloid binding in patients with dementia
with Lewy bodies and patients with Alzheimer’s disease [92,
93].
6. Conclusions
The PDFCD model provides a systematic assessment of cog-
nitive and behavioural symptoms, which may help clinicians
optimize therapeutic strategies. It also provides a framework
for hypothesis testing. For example, in prospective studies,
apathy should not appear before ICDs in most patients. The
model has a number of strengths and limitations. Among its
strengths, it is simple and ﬁts well clinical observations. For
example, it explains why depression can be present during
both OFF and ON periods, why depression and apathy
are diﬀerent disorders, and why some patients oscillate
between apathy and depression or between dementia and
psychosis. The combination of ON-period depression and
impulsivity (PDFCD stage IIa) is relevant to explain why
some PD subjects treated with subthalamic stimulation
attempt suicide [94, 95]. Among its limitations, the model
is in part ad hoc and does not contemplate region-speciﬁc
assessments of the direct dopaminergic projection to the
frontal cortex. In the early stages of PD, for example, cortical
dopamine upregulation might only involve the DLPFC [32,
33]. There is evidence to suggest that the dopaminergic
projection to the frontal cortex has limited capability for
adaptation in response to dopaminergic treatment, partic-
ularly levodopa, due to its lack of dopamine transporter
sites and dopamine D2 autoreceptors [38]. Still, treatment-
related psychosis occurring in PDFCD stage III could be
associated with relative dopaminergic hyperactivity in the
frontal cortex. In other words, frontal cortex “overdose” may
still be possible in later stages causing psychosis. Finally,
the model assumes that dopamine-dependent frontostriatal
functioning follows an inverted U-shaped dose-response
curve. Whereas this type of dopamine response seems to
operate in the frontal cortex [96], it might not necessarily
occur in the striatum. Additional model reﬁnements are
certainly needed, including a better deﬁnition of stages IIa
and IIb. To reach this goal, we need to develop better tools to
reliably distinguish between depression and apathy [97]a n d
reliably measure apathy and fatigue [98, 99].
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